

KEY INFORMATION DOCUMENT

Purpose

This document provides you with key information about this investment product. It is not marketing material. The information is required by law to help you understand the nature, risks, costs, potential gains and losses of this product and to help you compare it with other products.

RIZE MEDICAL CANNABIS AND LIFE SCIENCES UCITS ETF

PRODUCT

Product:	RIZE UCITS ICAV - RIZE MEDICAL CANNABIS AND LIFE SCIENCES UCITS ETF
Manufacturer name:	IQ EQ Fund Management (Ireland) Limited
Product code:	IE00BJXRZ273
Website:	www.rizeetf.com
Competent Authority:	IQ EQ Fund Management (Ireland) Limited is authorised in Ireland and regulated by Central Bank of Ireland. This PRIIP is authorised in Ireland.
Domicile country:	Ireland

Document valid as at: 31 December 2022

WHAT IS THIS PRODUCT?

Type:
UCITS


Term:
This product is not subject to any fixed term.

Objectives:
The Rize Medical Cannabis and Life Sciences UCITS ETF (the "Fund") is a passively managed exchange traded fund ("ETF") that aims to replicate the performance of the Foxberry Medical Cannabis & Life Sciences USD Net Total Return Index (the "Index").

Intended Retail Investor:

A typical Investor would be one who is a private or institutional investor and is seeking capital appreciation over the long term. Such an Investor is also one that is able to assess the merits and risks of an investment in the Shares of the relevant Class of the Fund.

WHAT ARE THE RISKS AND WHAT COULD I GET IN RETURN?



The risk indicator assumes you keep the product for 5 years. The actual risk can vary significantly if you cash in at an early stage and you may get back less. You may not be able to cash in early.

Risk indicator

The summary risk indicator is a guide to the level of risk of this product compared to other products. It shows how likely it is that the product will lose money because of movements in the markets or because we are not able to pay you.

We have classified this product as class 6 out of 7, which the second highest risk class. This rates the potential losses from future performance at a high level, and poor market conditions are very likely to impact the capacity of the fund to pay you.

Performance scenarios

What you will get from this product depends on future market performance. Market developments in the future are uncertain and cannot be accurately predicted.

The unfavourable, moderate, and favourable scenarios shown are illustrations using the worst, average, and best performance of the product / a suitable benchmark over the last 10 years. Markets could develop very differently in the future.

Recommended minimum holding period: 5 years Investment 10 000 USD			
Survival Scenarios Minimum:		1 year	5 years (recommended holding period)
Stress scenario	What might you get back after costs	640 USD	470 USD
	Average return each year	- 93.6 %	- 45.78 %
Unfavourable scenario	What might you get back after costs	3 510 USD	3 430 USD
	Average return each year	- 64.88%	- 19.25%
Moderate scenario	What might you get back after costs	10 720 USD	12 910 USD
	Average return each year	7.22%	5.24%
Favourable scenario	What might you get back after costs	25 940 USD	21 700 USD
	Average return each year	159.45%	16.76%

The figures shown include all the costs of the product itself, but may not include all the costs that you pay to your advisor or distributor. The figures do not take into account your personal tax situation, which may also affect how much you get back.
The stress scenario shows what you might get back in extreme market circumstances.
Unfavourable: This type of scenario occurred for an investment between 04/2021 and 08/2022.
Moderate: This type of scenario occurred for an investment between 01/2014 and 12/2018.
Favourable: This type of scenario occurred for an investment between 04/2016 and 03/2021.

WHAT HAPPENS IF IQ EQ FUND MANAGEMENT (IRELAND) LIMITED IS UNABLE TO PAY OUT?

You may face a financial loss should the Investment Manager or Depositary, Northern Trust Fiduciary Services (Ireland) Limited, default on their obligations. There is a compensation fund available for investors under the Investor Compensation Act, 1998 (the "Act") where the criteria for payment of compensation under the Act have been fulfilled. Further details are available from the Manager.

WHAT ARE THE COSTS?

The person advising on or selling you this product may charge you other costs. If so, this person will provide you with information about these costs and how they affect your investment.

Costs over Time

The tables show the amounts that are taken from your investment to cover different types of costs. These amounts depend on how much you invest, how long you hold the product and how well the product does. The amounts shown here are illustrations based on an example investment amount and different possible investment periods:

We have assumed:

- In the first year you would get back the amount that you invested (0% annual return). For the other holding periods we have assumed the product performs as shown in the moderate scenario.
- USD 10 000 is invested.

Investment 10 000 USD	If you exit after 1 year	If you exit after 5 years
Total costs	70 USD	458 USD
Annual Cost Impact*	0.7 %	0.74 %

*This illustrates how costs reduce your return each year over the holding period. For example it shows that if you exit at the recommended holding period your average return per year is projected to be 5.97% before costs and 5.24% after costs.

Composition of Costs

One-off costs upon entry or exit		If you exit after 1 year
Entry costs	We do not charge an entry fee for this product.	N/A
Exit costs	0% of your investment before it is paid out to you.	N/A
Ongoing costs		
Management fees and other administrative or operating costs	0.65%The ongoing charges are the running costs of the Fund, including distribution and marketing, but exclude transaction costs and performance fees.	65 USD
Portfolio transaction costs	0.04% of the value of your investment per year. This is an estimate of the costs incurred when we buy and sell the underlying investments for the product. The actual amount will vary depending on how much we buy and sell.	5 USD
Incidental costs taken under specific conditions		
Performance Fee	0.00%There is no performance fee for this product.	0 USD

HOW LONG SHOULD I HOLD IT AND CAN I TAKE MY MONEY OUT EARLY?

Recommended minimum holding period: 5 years

The above mentioned period has been defined in accordance to the product characteristics. It is determined on the basis of the fund's risk and reward profile. Your ideal holding period may be different from this minimum recommended holding period. We recommend that you discuss this with your advisor. If the holding period is shorter than the recommended minimum, this may have a negative impact on the fund's risk and reward profile. You may request to redeem the units held at any moment, in accordance with the Prospectus of the fund. Any costs are shown under "Composition of costs" above.

HOW CAN I COMPLAIN?

In the case of any unexpected problems in the understanding, trading or handling of the product, please feel free to directly contact IQ-EQ at the details below.

Website: iqeq.com
E-mail: ManCo@iqeq.com
Telephone: +353 1 673 5480

IQ-EQ will handle your request and provide you with a feedback as soon as possible.

OTHER RELEVANT INFORMATION

- Fund Depositary: Northern Trust Fiduciary Services (Ireland) Limited.
- The ICAV is resident in Ireland for taxation purposes. This may have an impact on your personal tax position. Please consult your investment or tax adviser for advice on your own tax liabilities.
- The Manager may be held liable solely on the basis of any statement contained in this document that is misleading, inaccurate or inconsistent with the relevant parts of the ICAV's Prospectus.
- Switching of shares between this Share Class and other share classes of the Fund and/or other sub-funds of the ICAV is not permitted.
- The Fund is one of a number of sub-funds of the ICAV. The assets and liabilities of each sub-fund are segregated from each other by Irish law. Although the rights of investors and creditors are normally limited to the assets of each sub-fund, the ICAV is a single legal entity that may operate in jurisdictions which may not recognise such segregation.
- Further information about the Fund and the Share Class can be obtained from the ICAV's Prospectus and Fund Supplement and the annual and interim financial statements (that are prepared for the ICAV as a whole), which are available in English and certain other languages, in addition to the latest available Net Asset Value for the Share Class and details of the Fund's portfolio, at: <http://www.rizeetf.com>
- Details of the Manager's up-to-date policy in respect of remuneration, including a description of how remuneration and benefits are calculated and the identities of the persons responsible for awarding same can be accessed from the following website: www.iqeq.com/policy-documents
- An indicative intra-day net asset value ("iNAV") for the Share Class will be available at: <http://www.rizeetf.com>
- Alongside this document, we invite you to carefully consult the Fund Supplement and Prospectus on our website.
- The past performances of this product can be found here https://api.kneip.com/v1/documentdata/permalinks/KPP_IE00BJXRZ273_en_IE.pdf. Please note that past performance is not indicative of future performance. It cannot provide a guarantee of returns that you will receive in the future.
- The previous scenarios document for this product can be found here https://api.kneip.com/v1/documentdata/permalinks/KMS_IE00BJXRZ273_en_IE.csv